Literature DB >> 12112018

Purification and characterization of protein tyrosine phosphatase PTP-MEG2.

Ying Qi1, Runxiang Zhao, Hongxi Cao, Xingwei Sui, Sanford B Krantz, Z Joe Zhao.   

Abstract

PTP-MEG2 is an intracellular protein tyrosine phosphatase with a putative lipid-binding domain at the N-terminus. The present study reports expression, purification, and characterization of the full-length form of the enzyme plus a truncated form containing the catalytic domain alone. Full-length PTP-MEG2 was expressed with an adenovirus system and purified from cytosolic extracts of human 293 cells infected with the recombinant adenovirus. The purification scheme included chromatographic separation of cytosolic extracts on fast flow Q-Sepharose, heparin-agarose, l-histidyldiazobenzylphosphonic acid agarose, and hydroxylapatite. The enrichment of PTP-MEG2 from the cytosol was about 120-fold. The truncated form of PTP-MEG2 was expressed in E. coli cells as a non-fusion protein and purified by using a chromatographic procedure similar to that used for the full-length enzyme. The purified full-length and truncated enzymes showed single polypeptide bands on SDS-polyacrylamide gel electrophoresis under reducing conditions and behaved as monomers on gel exclusion chromatography. With para-nitrophenylphosphate and phosphotyrosine as substrates, both forms of the enzyme exhibited classical Michaelis-Menten kinetics. Their responses to pH, ionic strength, metal ions, and protein phosphatase inhibitors are similar to those observed with other characterized tyrosine phosphatases. Compared with full-length PTP-MEG2, the truncated DeltaPTP-MEG2 displayed significantly higher V(max) and lower K(m) values, suggesting that the N-terminal putative lipid-binding domain may have an inhibitory role. The full-length and truncated forms of PTP-MEG2 were also expressed as GST fusion proteins in E. coli cells and purified to near homogeneity through affinity columns. However, the specific phosphatase activities of the GST fusion proteins were 10-25-fold below those obtained with the correspondent non-fusion proteins. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12112018     DOI: 10.1002/jcb.10195

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  5 in total

Review 1.  Modulation of VEGF receptor 2 signaling by protein phosphatases.

Authors:  Federico Corti; Michael Simons
Journal:  Pharmacol Res       Date:  2016-11-23       Impact factor: 7.658

2.  Tyrosine phosphatase PTP-MEG2 negatively regulates vascular endothelial growth factor receptor signaling and function in endothelial cells.

Authors:  Qin Hao; Buka Samten; Hong-Long Ji; Z Joe Zhao; Hua Tang
Journal:  Am J Physiol Cell Physiol       Date:  2012-07-03       Impact factor: 4.249

3.  Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer.

Authors:  Fuqin Su; Fangli Ren; Yu Rong; Yangmeng Wang; Yongtao Geng; Yinyin Wang; Mengyao Feng; Yanfang Ju; Yi Li; Zhizhuang J Zhao; Kun Meng; Zhijie Chang
Journal:  Breast Cancer Res       Date:  2012-03-06       Impact factor: 6.466

4.  MEG2 is regulated by miR-181a-5p and functions as a tumour suppressor gene to suppress the proliferation and migration of gastric cancer cells.

Authors:  Zhijian Liu; Feng Sun; Yeting Hong; Yanqing Liu; Min Fen; Kai Yin; Xiaolong Ge; Feng Wang; Xi Chen; Wenxian Guan
Journal:  Mol Cancer       Date:  2017-07-26       Impact factor: 27.401

5.  Synthesis, bioactivity, 3D-QSAR studies of novel dibenzofuran derivatives as PTP-MEG2 inhibitors.

Authors:  Ying Ma; Hui-Yu Wei; Yu-Ze Zhang; Wen-Yan Jin; Hong-Lian Li; Hui Zhou; Xian-Chao Cheng; Run-Ling Wang
Journal:  Oncotarget       Date:  2017-06-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.